As biotech startups sing the blues over 2012 VC deals, others hum a new tune
This article was originally published in Scrip
Executive Summary
Venture capital investment in US biotechnology companies ended 2012 on a low note with just $4.1 billion invested in the industry versus the $4.9 billion in 2011. The decline was even more dramatic for startups, since first-time investments in early-stage firms were cut by more than half from $922.3 million to $438.3 million last year.